SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 1,030.71 |
| Enterprise Value ($M) | 910.21 |
| Book Value ($M) | 962.62 |
| Book Value / Share | 9.45 |
| Price / Book | 1.07 |
| NCAV ($M) | 500.17 |
| NCAV / Share | 4.91 |
| Price / NCAV | 2.06 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.49 |
| Return on Assets (ROA) | -0.40 |
| Return on Equity (ROE) | -0.50 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.73 |
| Current Ratio | 6.73 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 710.90 |
| Assets | 1,173.35 |
| Liabilities | 210.74 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | |||
| 13G/A | ARK Investment Management LLC | 12.74 | 21.14 | |
| 13G/A | State Street Corp | 5.29 | 179.65 | |
| 13G/A | BlackRock, Inc. | 10.10 | 24.20 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 407,835 | 1,758,859 | 23.19 | |
| 481,551 | 2,232,180 | 21.57 | |
| 374,566 | 2,528,652 | 14.81 | |
| 444,298 | 2,213,800 | 20.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NGNE – Neurogene Inc. | NKGN – NKGen Biotech, Inc. |
| NRIX – Nurix Therapeutics, Inc. | OCS – Oculis Holding AG |
| OCUL – Ocular Therapeutix, Inc. |
Financial data and stock pages provided by
Fintel.io